Jim Simons Athira Pharma, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 262,324 shares of ATHA stock, worth $695,158. This represents 0.0% of its overall portfolio holdings.

Number of Shares

262,324

Previous 265,400 1.16%

Holding current value

$695,158

Previous $645,000 11.47%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.24 - $4.15 $6,890 - $12,765	-3,076 Reduced 1.16%	262,324 $719,000
Q4 2023 Feb 13, 2024	SELL	$1.39 - $2.46 $24,325 - $43,050	-17,500 Reduced 6.19%	265,400 $645,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $3.16 $296,210 - $492,644	-155,900 Reduced 35.53%	282,900 $571,000
Q2 2023 Aug 11, 2023	BUY	$2.36 - $3.59 $299,566 - $455,696	126,935 Added 40.7%	438,800 $1.29 Million
Q1 2023 May 12, 2023	BUY	$2.26 - $4.22 $519,268 - $969,608	229,765 Added 279.86%	311,865 $780,000

Q4 2022 Feb 13, 2023	SELL	$2.76 - $3.37 $422,012 - $515,283	-152,903 Reduced 65.06%	82,100 $260,000
Q3 2022 Nov 14, 2022	BUY	$3.12 - $3.96 $733,209 - $930,611	235,003 New	235,003 $698,000
Q2 2022 Aug 12, 2022	SELL	$2.74 - $13.43 $102,476 - $502,282	-37,400 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$8.96 - $13.51 $684,544 - $1.03 Million	-76,400 Reduced 67.14%	37,400 $505,000
Q4 2021 Feb 11, 2022	BUY	$9.17 - $16.39 $559,984 - $1 Million	61,067 Added 115.8%	113,800 $1.48 Million
Q3 2021 Nov 12, 2021	BUY	$9.15 - $11.09 $482,506 - $584,808	52,733 New	52,733 $495,000

Others Institutions Holding ATHA

# of Institutions

Shares Held

22.3M

Call Options Held

77.1K

Put Options Held

42.4K

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $100M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account